Invest in RS BioTherapeutics

CLOSED

Developing a Novel Drug Platform to Address Deadly Lung Diseases

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

REASONS TO INVEST

ABOUT

HEADQUARTERS

TERMS

RS BioTherapeutics

Overview

INTEREST RATE

5.0%

MATURITY DATE

Apr 25, 2026

DEADLINE

Jul. 30, 2024 at 6:59 AM UTC

VALUATION CAP

$40M

FUNDING GOAL

$10K - $1.24M

Breakdown

MIN INVESTMENT

$500

DISCOUNT

15.0%

CONVERSION TRIGGER

$1,000,000

OFFERING TYPE

Convertible Notes

TYPE OF EQUITY

Series Seed-1 Preferred Stock

Most Recent Fiscal Year-End

Prior Fiscal Year-End

Total Assets

$31,300

$1,527,085

Cash & Cash Equivalents

$4,979

$1,502,397

Accounts Receivable

Short-Term Debt

$1,051,533

$1,025,615

Long-Term Debt

$10,104

$24,056

Revenue & Sales

Costs of Goods Sold

Taxes Paid

Net Income

-$3,047,449

-$2,083,273

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.

A convertible note offers you the right to receive Series Seed-1 Preferred Stock in RS BioTherapeutics. The amount of Series Seed-1 Preferred Stock you will receive in the future will be determined at the next equity round in which the Company raises at least $1,000,000.00 in a qualified equity financing. The highest conversion price per security is set based on a $40,000,000.00 Valuation Cap or if less, then you will receive a 15.00% discount on the price the new investors are paying. You also receive 5.00% interest per year added to your investment. When the maturity date is reached, if the note has not converted then you are entitled to receive Series Seed-1 Preferred Stock equal to your investment and interest back at a price per security determined by dividing the Valuation Cap by the aggregate number of outstanding equity securities of the Company as of immediately prior (on a fully diluted basis).

*Annual Interest Rate subject to adjustment of bonus interests rates below.

Investment Incentives and Bonuses*

Loyalty bonus - 50% bonus interest rate

Time-Based Perk

Early Bird

Invest within the first 2 weeks | get 40% bonus interest on your interest rate

Amount-Based Perks

Tier 1 Perk — Invest $10,000+ and receive 20% bonus interest on your interest rate

Tier 2 Perk — Invest $25,000+ and receive 30% bonus interest on your interest rate

Tier 3 Perk — Invest $50,000+ and receive a 50% bonus interest on your interest rate

*All perks occur when the offering ends.

The 10% StartEngine Venture Club Bonus

RS BioTherapeutics, Inc. will offer 10% additional bonus interest for all investments that are committed by investors that are eligible for the StartEngine Venture Club.

Eligible StartEngine shareholders will receive a 10% increase in the annual interest rate on Convertible Promissory Notes in this Offering. This means your annual interest rate will be 5.5% instead of 5%.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Venture Club bonus and the loyalty bonus in addition to the aforementioned bonus.

Irregular Use of Proceeds

We will not incur any irregular use of proceeds.

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

FAQS

More FAQs